Abstract 784: Andrographolide altered inflammation pathways and cytokine expression in prostatecancer

Abstract

Abstract Prostate cancer is the most diagnosed cancer in men in the USA. Andrographolide (AG) is a labdane diterpenoid compound isolated from the medicinal plant Andrographis paniculata. Previous studies in our laboratory showed that Andrographolide decreased prostate tumor size in mice, induced expression of DNA repair genes associated with double-strand break repair and altered mitochondrial function. The objective of this study is to determine the role of AG in inflammation in prostate cancer. Microarray analysis of tumors treated with Andrographolide 10 mg/kg and their vehicle were conducted. Tumors were developed using a xenograft model in which the prostates of SCID mice were injected with 22RV1, and mice were treated three times per week with Andrographolide 10 mg/kg. Tumor tissues were collected and snap frozen. Gene expression was identified and analyzed using the Affymetrix GeneChip® Human Gene 2.0 array. Using Ingenuity Pathway Analysis (IPA) we found that Andrographolide 10 mg/kg altered genes associated with inflammatory response such as ATM, DHFR, HIF-1-α, CDKAL1, DHFR, NOX1, C5, CCL4, COG6, SUPT20H, CA5B, TTC3. To determine changes of cytokine expression in PC3 prostate cancer cells treated with 25 μM Andrographolide, we used the Abcam Cytokine Antibody Array test®. PC3 prostate cancer cells treated with Andrographolide showed altered expression of cytokines such as IL-2, TNF-α, TNF-β, EGF, IGF-1, ENA-78, GM-CSF, GRO, GRO-α, I-309, and Angiogenin. These results showed that AG may alter the tumor microenvironment promoting the secretion of diverse cytokines that may inhibit tumor development. Understanding these biological pathways and networks is essential to determine possible targets of Andrographolide in prostate cancer. Citation Format: Mitzy J. Santiago Rosario, Gabriela Erazo Carde, María Sánchez Vázquez, Valerie Cardona, Magaly Martínez Ferrer. Andrographolide altered inflammation pathways and cytokine expression in prostatecancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 784.